Provider Alert! Implementation of Hereditary Angioedema (HAE) Agents Clinical Prior Authorization for Fee for Service Scheduled for April 11
Date: May 10, 2023 Attention: Providers Effective Date: April 11, 2023 Call to action: Effective April 11, 2023 Texas Health and Human Services Commission (HHSC) added Takhzyro generic code (GCN) 39478 to the drugs requiring Hereditary Angioedema (HAE) clinical prior authorization for clients enrolled in Medicaid Fee-For-Service. How this impacts providers: Prescribers will now have to submit a prior authorization for Takhzyro® for their Medicaid fee-for-service population. Next steps for providers: Prescribers should share this communication with their staff. Provider must submit documentation (such as...
